No Data
No Data
10-K: FY2024 Annual Report
TriSalus Life Sciences Reports Strong Growth Amid Challenges
Express News | TriSalus Life Sciences - Working Diligently to Evaluate Materiality of Errors
Express News | TriSalus Life Sciences-Identified Errors in Timing of Stock-Based Compensation Expense, Clinical Trial Related Expenses. Use of Incorrect Assumptions
Express News | TriSalus Life Sciences Inc Files Non-Timely 10-K With U.S. SEC
Roth MKM Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $11